PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-2.84
Negative P/E while Biotechnology median is -5.20. Seth Klarman would scrutinize path to profitability versus peers.
No Data
No Data available this quarter, please select a different quarter.
4.29
P/B 1.1-1.25x Biotechnology median of 3.90. John Neff would demand superior ROE to justify premium.
-18.51
Negative FCF while Biotechnology median P/FCF is -26.19. Seth Klarman would investigate cash flow improvement potential.
-18.52
Negative operating cash flow while Biotechnology median P/OCF is -25.50. Seth Klarman would investigate operational improvement potential.
4.29
Fair value ratio 1.1-1.25x Biotechnology median of 3.87. John Neff would demand superior metrics to justify premium.
-8.80%
Negative earnings while Biotechnology median yield is -2.71%. Seth Klarman would investigate path to profitability.
-5.40%
Negative FCF while Biotechnology median yield is -1.82%. Seth Klarman would investigate cash flow improvement potential.